| Literature DB >> 17439661 |
Steffen Christensen1, Anders Riis, Mette Nørgaard, Henrik T Sørensen, Reimar W Thomsen.
Abstract
BACKGROUND: Mortality after perforated and bleeding peptic ulcer increases with age. Limited data exist on how the higher burden of comorbidity among elderly patients affects this association. We aimed to examine the association of age with short-term mortality after perforated and bleeding peptic ulcer and to determine the impact of comorbidity on this association.Entities:
Mesh:
Year: 2007 PMID: 17439661 PMCID: PMC3225863 DOI: 10.1186/1471-2318-7-8
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Characteristics of 2,061 patients with perforated and 7,232 patients with bleeding peptic ulcer in the counties of North Jutland, Aarhus and Viborg, Denmark.
| Perforated peptic ulcer | Bleeding peptic ulcer | |||||
|---|---|---|---|---|---|---|
| Female | 338 (42.0%) | 410 (55.2%) | 358 (69.8%) | 739 (35.5%) | 1329 (47.1%) | 1402 (59.1%) |
| Male | 467 (58.0%) | 333 (44.8%) | 155 (30.2%) | 1347 (64.6%) | 1445 (52.1%) | 970 (40.9%) |
| Use† | 484 (60.1%) | 554 (74.6%) | 417 (81.3%) | 1434 (68.7%) | 2093 (75.4%) | 1950 (82.2%) |
| No use | 321 (39.9%) | 189 (25.4%) | 96 (18.7%) | 652 (31.3%) | 681 (24.6%) | 422 (17.8%) |
| No | 709 (88.1%) | 657 (88.4%) | 463 (90.3%) | 1829 (87.5%) | 2446 (88.2%) | 2115 (89.2%) |
| Yes | 96 (11.9%) | 86 (11.6%) | 50 (9.7%) | 257 (12.6%) | 328 (11.8%) | 257 (10.8%) |
| Low | 616 (76.5%) | 378 (50.9%) | 273 (53.2%) | 1442 (68.2%) | 1322 (47.7%) | 1148 (48.4%) |
| Moderate | 161 (20.0%) | 290 (39.0%) | 208 (40.6%) | 523 (25.1%) | 1139 (41.0%) | 1013 (42.7%) |
| High | 28 (3.5%) | 75 (10.1%) | 32 (6.2%) | 141 (6.7%) | 313 (11.3%) | 212 (8.9%) |
*For perforated peptic ulcer "ulcer-related drugs" are: oral glucocorticoids, NSAIDs and aspirin. For bleeding peptic ulcer "ulcer-related drugs" are: non-aspirin NSAIDs, aspirin, oral glucocorticoids, vitamin K antagonists, calcium channel blockers, and/or antidepressants
† Use = filled prescription 60 days before admission with perforated peptic ulcer.
# Three levels of the index were defined: Low (no co-morbidity), medium (Charlson index 1–2) and high (Charlson index 2+).
Crude and standardized 30-day mortality for patients with a first-time discharge diagnosis of perforated or bleeding peptic ulcer and 30-day mortality rate ratios (MRRs) relative to patients aged 15–64.
| Age groups | Number of patients | 30-day mortality | Standardized 30-day mortality ∞ (95% CI) | Crude 30-day MRR (95% CI) | Adjusted 30-day MRR# (95% CI) |
|---|---|---|---|---|---|
| 15–64 | 805 | 8.9% | 8.9% (7.0%–10.9%) | 1 (ref) | 1 (ref) |
| 65–79 | 743 | 28.5% | 24.2% (20.7%–27.6%) | 3.5 (2.7–4.6) | 2.8 (2.1–3.6) |
| 80+ | 513 | 46.0% | 44.6% (38.8%–50.5%) | 6.6 (5.1–8.6) | 5.3 (4.1–7.0) |
| 15–64 | 2086 | 4.3% | 4.3% (3.4%–5.2%) | 1 (ref) | 1 (ref) |
| 65–79 | 2774 | 10.2% | 8.7% (7.6%–9.9%) | 2.4 (1.9–3.1) | 2.2 (1.7–2.8) |
| 80+ | 2372 | 17.0% | 16.9% (15.0%–18.7%) | 4.2 (3.3–5.3) | 3.7 (2.9–4.7) |
∞ Standardized to the distribution of gender and comorbidity in the youngest age group.
# Adjusted by Cox regression analysis for gender, comorbidity prior to hospitalisation with complicated peptic ulcer, use of ulcer-related drugs and previous admissions with uncomplicated peptic ulcer.
Figure 1Survival of patients with perforated (A) and bleeding peptic ulcer (B) according to age group. Aarhus, North Jutland and Viborg counties, Denmark.
30-day mortality and mortality rate ratios (MRR) for patients with perforated and bleeding peptic ulcer stratified by level of comorbidity.
| Age (years) | Number of patients | 30-day mortality | Crude 30-day MRR (95% CI) | Adjusted 30-day MRR* (95% CI) | |
|---|---|---|---|---|---|
| Low | 15–64 | 616 | 6.0% | 1 (ref) | 1 (ref) |
| 65–79 | 378 | 20.9% | 3.8 (2.5–5.6) | 3.5 (2.3–5.1) | |
| 80+ | 273 | 41.0% | 8.6 (5.9–12.4) | 8.1 (5.5–11.9) | |
| Moderate | 15–64 | 161 | 16.8% | 1 (ref) | 1 (ref) |
| 65–79 | 290 | 34.8% | 2.3 (1.5–3.4) | 2.1 (1.4–3.2) | |
| 80+ | 208 | 50.0% | 3.8 (2.5–5.7) | 3.4 (2.3–5.3) | |
| High | 15–64 | 28 | 28.6% | 1 (ref) | 1 (ref) |
| 65–79 | 75 | 42.7% | 1.6 (0.8–3.6) | 1.6 (0.7–3.6) | |
| 80+ | 32 | 62.5% | 3.0 (1.3–6.7) | 2.9 (1.2–6.8) | |
| Low | 15–64 | 1422 | 3.4% | 1 (ref) | 1 (ref) |
| 65–79 | 1322 | 6.7% | 2.0 (1.4–2.9) | 1.9 (1.3–2.7) | |
| 80+ | 1148 | 16.0% | 4.9 (3.6–6.8) | 4.5 (3.3–6.2) | |
| Moderate | 15–64 | 523 | 5.5% | 1 (ref) | 1 (ref) |
| 65–79 | 1139 | 13.4% | 2.5 (1.7–3.7) | 2.5 (1.7–3.7) | |
| 80+ | 1012 | 16.9% | 3.2 (2.2–4.8) | 3.2 (2.2–4.8) | |
| High | 15–64 | 141 | 9.2% | 1 (ref) | 1 (ref) |
| 65–79 | 313 | 13.7% | 1.5 (0.8–2.8) | 1.5 (0.8–2.7) | |
| 80+ | 212 | 25.0% | 2.9 (1.6–5.1) | 2.7 (1.5–4.9) | |
Ω Three levels of the index were defined: Low (no co-morbidity), medium (Charlson Index 1–2) and high (Charlson Index 3+). * Adjusted in a Cox regression model for gender, previous admissions with uncomplicated peptic ulcer and ulcer-related drug use.